Latest News and Press Releases

– Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M – Unaudited cash of at least $248M, updates guidance with cash into 2024 – BOLD Phase 3 study in biliary atresia is over 50%...

– First oral, systemic ASBT inhibitor was safe and well tolerated – Secondary and exploratory objectives show favorable pharmacokinetics and systemic exposure, while providing target engagement...

– Data show significant correlations in serum bile acid reductions and long-term improvements in pruritus and sleep – Reductions in serum bile acids and improvements in pruritus with and without...

BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn,...

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the appointment of Constantine...

– Evidence of long-term clinical treatment benefit of Bylvay™ (odevixibat) showing improved liver health and function across PFIC types – – Data show Bylvay therapy up to 128 weeks, sustained...

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...

– Bylvay™ (odevixibat) approved in the U.S. and Europe, partial Q3 ’21 revenue of $1.1 million– – ASSERT & BOLD Phase 3 studies enrolling, on track for topline data readouts – – 12 abstracts...

BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...

– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases – – Phase 3 Bylvay™ (odevixibat) data presentations on long-term treatment benefits show evidence of...